The deal with Personal Genome Diagnostics, effected through Qiagen???s Ipsogen subsidiary, gives the firm exclusive rights to IDH1/IDH2 mutations, which Personal Genome Diagnostics claims are associated with brain cancers, acute myelogenous leukemia, and other cancers.